OC
PETX

Oppenheimer & Co’s Aratana Therapeutics, Inc. PETX Stock Holding History

Oppenheimer & Co’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-14,000
Closed -$211K – 1507
2015
Q2 		$211K Buy
+14,000
New +$202K 0.01% 1272

Other funds holding PETX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Oppenheimer & Co's PETX Position: Q3 2015 in Review

Oppenheimer & Co sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2015, closing a stake of 14,000 shares — an estimated $211K sold.

Oppenheimer & Co first reported a position in PETX in Q2 2015 and held it in 1 quarter. The position peaked at $211K in Q2 2015. 103 funds tracked by Wall St. Rank hold PETX as of Q3 2015.

  • Oppenheimer & Co reported no remaining Aratana Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Oppenheimer & Co sold 14,000 Aratana Therapeutics, Inc. shares in Q3 2015, an estimated $211K.
  • Oppenheimer & Co first reported a position in Aratana Therapeutics, Inc. in Q2 2015 and held it in 1 quarter.
  • Oppenheimer & Co's Aratana Therapeutics, Inc. position peaked at $211K in Q2 2015.
  • 103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2015.

Based on Oppenheimer & Co's 13F filing for Q3 2015, filed 13 Nov 2015.